Vaccine injection and preparation method thereof

By using aluminum gel adjuvant in vaccine injections to adsorb and sustainably release inactivated bacterial solution and immune enhancer, the problem of difficulty in maintaining the concentration ratio of vaccines and immune enhancer in vivo is solved, and better immune effect and safety are achieved.

CN118403149BActive Publication Date: 2024-11-22深圳市龙华区中心医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410069182.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-17
Publication Date
2024-11-22
Estimated Expiration
2044-01-17

AI Technical Summary

Technical Problem

There are differences in the transportation and metabolism of vaccines and immune enhancers in the human body, which makes it unable to maintain a suitable concentration ratio in the body, affecting the immune effect.

Method used

Using a vaccine injection preparation method, by providing a colloidal aluminum adjuvant dispersion, adsorbing inactivated bacterial solution and immunoenhancing agent to form colloidal precipitation, and mixing it with the injection solvent, ensuring sustained release of antigens and immunoenhancing agents to gradually increase its concentration to ensure the appropriate proportions in various areas in the body.

Benefits of technology

Through the sustained release effect of aluminum glue adjuvant, we ensure that the antigen and immune enhancer maintain a better concentration ratio in the body in time and space, improve the immune effect, avoid the risk of hemolysis caused by free substances, prolong the action time, and enhance immune ability.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a vaccine injection and a preparation method thereof, wherein the preparation method comprises the following steps: providing a colloidal aluminum gel adjuvant dispersion liquid with an aluminum ion content of 0.3 to 1.5 mg / ml, an inactivated bacterial solution and an immunopotentiator, and separating the colloidal precipitate after mixing; and mixing the colloidal precipitate with an injection solvent to obtain the vaccine injection. The prepared vaccine injection can maintain a better concentration ratio of the antigen and the immunopotentiator in time and space, thereby improving the immune effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of vaccines, in particular to vaccine injections and a preparation method thereof. Background Art

[0002] Aluminum gel adjuvant is a milky white gel semisolid, including aluminum hydroxide gel, etc. It forms antigen aggregates by adsorbing protein antigens and slowly releases antigens in the body, thereby prolonging the action time of antigens. It is widely used in various vaccines. Immunoenhancers are a type of substance that can enhance the body's immune response. Combining vaccines with immunoenhancers can further enhance the effectiveness of vaccines. However, there are differences in the transportation and metabolism of vaccines and immunoenhancers in the human body, resulting in the inability to maintain a more appropriate concentration ratio between vaccines and immunoenhancers in different regions and at different times in the body, making it impossible to further improve the immune effect.

[0003] Improving the preparation method of vaccine injection will help further enhance the immune effect of the vaccine on the human body. Summary of the invention

[0004] Based on this, it is necessary to provide a vaccine injection and a preparation method thereof.

[0005] A method for preparing a vaccine injection comprises the following steps:

[0006] Providing a colloidal aluminum gel adjuvant dispersion liquid with an aluminum ion content of 0.3 to 1.5 mg / ml, an inactivated bacterial solution and an immunopotentiator, and separating the colloidal precipitate after mixing;

[0007] The colloid precipitate is mixed with an injection solvent to obtain the vaccine injection.

[0008] In this scheme, the fire-killing bacteria liquid and the immunopotentiator are adsorbed together by the aluminum gel adjuvant to form a colloidal precipitate, and the colloidal precipitate is separated and mixed with an injection solvent to form a vaccine injection, thereby ensuring that there is no free inactivated bacteria liquid (i.e., antigen) and immunopotentiator in the vaccine injection. After the vaccine injection is injected into the body, the antigen and the immunopotentiator are continuously released by the sustained-release effect of the aluminum gel adjuvant, so that the concentration of the antigen and the immunopotentiator gradually increases from 0 to approaching equilibrium. The antigen and the immunopotentiator are slowly released in various regions of the body as the aluminum gel adjuvant is transported, which can ensure that the antigen and the immunopotentiator maintain a better concentration ratio in time and space, thereby improving the immune effect.

[0009] Specifically, the injection solvent includes at least one of water, physiological saline or phosphate buffer. These liquids can be used as diluents for the colloid precipitate, making the colloid precipitate fluid and suitable for the condition in the recipient body.

[0010] In one embodiment, the preparation method of the aluminum gel adjuvant dispersion liquid in a colloidal state and having an aluminum ion content of 0.3 to 1.5 mg / ml comprises: taking an aluminum salt solution, gradually adding a water-soluble base during stirring, separating the aluminum gel adjuvant and adding deionized water to obtain an aluminum gel adjuvant dispersion liquid in a colloidal state and having an aluminum ion content of 0.3 to 1.5 mg / ml. Through this step, a colloidal aluminum gel adjuvant dispersion liquid can be obtained, and the colloidal aluminum gel adjuvant can absorb the inactivated bacterial solution and the immunopotentiator well, thereby fixing the inactivated bacterial solution and the immunopotentiator in the particles of the aluminum gel adjuvant, playing a role of synchronous sustained release, and enhancing the immune ability of the recipient.

[0011] In one embodiment, the water-soluble base is one of sodium hydroxide and ammonia water, which are commonly used to prepare aluminum gel adjuvants, thereby obtaining aluminum gel adjuvants with higher purity and greater safety.

[0012] In one embodiment, before the step of adding the inactivated bacterial solution and the immunopotentiator to the aluminum gel adjuvant dispersion, the step further includes:

[0013] The steps of preparing bacterial solution are as follows: after reviving the freeze-dried strain in CLBA blood plate, a single bacterial colony is selected and inoculated into the first LB culture medium, cultured with shaking, and the first generation of strains is obtained after the purity test is qualified; a single bacterial colony from the first generation of strains is selected and inoculated into the first CLBA culture medium for further culture, and the second generation of strains is obtained after the purity test is qualified; a single bacterial colony from the second generation of strains is selected and cultured in the second LB culture medium, and after the purity test is qualified, it is inoculated into a new third LB culture dish at 1%, cultured with shaking, and the next step is performed after the purity test is qualified; specifically, the freeze-dried strain is inoculated into the first LB culture medium, cultured with shaking, and the first generation of strains is obtained after the purity test is qualified; After revival in CLBA blood plate, select single colony bacteria and inoculate them into the first LB culture medium, shake culture at 35-40℃ for 16-24h, and obtain the first generation strain after passing the purity test; select single colony from the first generation strain and inoculate it into the first CLBA culture medium for further culture, and obtain the second generation strain after passing the purity test; select single colony from the second generation strain and culture it in the second LB culture medium, and inoculate it into the third LB culture dish at 1% after passing the purity test, shake culture at 35-40℃ for 18-24h, and proceed to the next step after passing the purity test;

[0014] Inactivation step: adding formaldehyde solution and sealing treatment, taking samples and inoculating the second CLBA culture medium for sterility test, and proceeding to the next step after passing the test; specifically, adding formaldehyde solution to a final concentration of 0.1-0.3%, sealing treatment at 35-40°C for 16-32h, shaking once every 4-6h, taking samples and inoculating the second CLBA culture medium for sterility test, and proceeding to the next step after passing the test;

[0015] Bacterial liquid concentration step: The bacterial liquid was centrifuged, the obtained bacterial sludge was washed at least three times and then suspended into bacterial liquid, and the concentration of the bacterial liquid was adjusted to 1×10 9 ~3×10 9 CFU / ml, and obtain an inactivated bacterial solution; specifically, the bacterial solution was placed in a centrifuge at 2000-4000 rpm for 10-30 min, the obtained bacterial sludge was washed at least three times and then suspended into a bacterial solution, and the concentration of the bacterial solution was adjusted to 1×10 9 ~3×10 9 CFU / ml, and obtain the inactivated bacterial solution.

[0016] The above-mentioned preparation steps can produce a high purity inactivated bacterial solution, which is suitable for injection into a recipient to play an immune role.

[0017] In one embodiment, the aluminum gel adjuvant includes at least one of aluminum hydroxide and aluminum phosphate, and the aluminum hydroxide and aluminum phosphate can both play a good role in absorbing inactivated bacteria and immunopotentiators, and are relatively non-toxic, and can increase the immune ability of the recipient. Specifically, the particle size of the aluminum hydroxide is 2 to 20 nm, and the particle size of the aluminum phosphate is 50 to 100 nm. This particle size range can better produce a colloidal aluminum gel adjuvant.

[0018] A vaccine injection is prepared by the vaccine injection preparation method as described in any of the above embodiments. DETAILED DESCRIPTION

[0019] For ease of understanding of the present application, the present application will be described more fully below with reference to the relevant embodiments. Preferred embodiments of the present application are provided in the embodiments. However, the present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present application more thorough and comprehensive.

[0020] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of the application, the meaning of "multiple" is at least two, such as two, three, etc., unless otherwise clearly and specifically defined. In the description of the present application, the meaning of "several" is at least one, such as one, two, etc., unless otherwise clearly and specifically defined.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the present application belongs. The terms used herein in the specification of the present application are only for the purpose of describing specific embodiments and are not intended to limit the present application. The term "and / or" used herein includes any and all combinations of one or more of the related listed items.

[0022] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0023] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0024] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.

[0025] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0026] The temperature parameters in this application, unless otherwise specified, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range of instrument control.

[0027] The "particles" mentioned in this application, or materials with a defined particle size distribution, are not necessarily spherical in shape, but may be irregular, primary particles or secondary particles. The particle size of irregular particles is the average of their maximum diameter and minimum diameter.

[0028] In one embodiment, a method for preparing a vaccine injection is provided, comprising the following steps:

[0029] S1: Take an aluminum salt solution and gradually add a water-soluble base during stirring to prepare a colloidal aluminum gel adjuvant dispersion with an aluminum ion content of 0.3 to 1.5 mg / ml.

[0030] S2: Provide a colloidal aluminum gel adjuvant dispersion with an aluminum ion content of 0.3-1.5 mg / ml and a bacterial solution concentration of 1×109 ~3×10 9 CFU / ml of inactivated bacteria solution of Riemerella anatipestifer and houttuynia cordata sodium with a concentration range of 1-3 mg / ml.

[0031] S3: adding sodium houttuynia cordata and the inactivated bacterial solution of Riemerella anatipestifer to the aluminum gel adjuvant dispersion, wherein the volume ratio of sodium houttuynia cordata, the inactivated bacterial solution of Riemerella anatipestifer and the aluminum adjuvant dispersion is 1:(1-10):(1-20), and after mixing, separating the colloidal precipitate.

[0032] S4: Mix the colloidal precipitate with an injection solvent to obtain a vaccine injection.

[0033] The preparation method of the vaccine injection of the present application, the prepared vaccine injection can be inoculated into the recipient body, wherein the aluminum gel adjuvant can adsorb the antigen and houttuynia cordata sodium of the inactivated bacterial solution of Riemerella anatipestifer through electrostatic adsorption, so that the antigen and houttuynia cordata sodium react with the aluminum gel adjuvant to form a complex, so that the antigen and houttuynia cordata sodium will stably bind to the aluminum gel adjuvant. After separating the colloid precipitate, the mixed injection solvent is injected into the recipient body, and the aluminum gel adjuvant can synchronously and slowly release the inactivated bacterial solution and houttuynia cordata sodium, fully extending the action time of the inactivated bacterial solution and houttuynia cordata sodium, and can continuously maintain the inactivated bacterial solution and houttuynia cordata sodium in the recipient body at different time and space. The better concentration ratio of the two can continue to play an efficient immune effect without causing hemolysis of the recipient. At the same time, in the process of releasing the inactivated bacterial solution and houttuynia cordata sodium, the aluminum gel adjuvant plays an immunoenhancing role and increases the immune ability of the recipient. That is, the aluminum gel adjuvant can play a sustained release role on the one hand, avoiding the premature consumption of the inactivated bacterial solution, and maintaining the inactivated bacterial solution and houttuynia cordata sodium at an appropriate concentration ratio, and on the other hand, it can also play an immunopotentiating role, further improving the immune ability of the recipient. Furthermore, after the aluminum gel adjuvant adsorbs the houttuynia cordata sodium and the inactivated bacterial solution, the colloidal precipitate is separated and then mixed with the injection solvent, so that the free houttuynia cordata sodium and the inactivated bacterial solution are removed in the separation stage, avoiding hemolysis of the recipient.

[0034] In order to avoid the experiment causing harm to people, the following is an example of assisting lace ducks to be immunized against Riemerella anatipestifer. Riemerella anatipestifer is a contact infectious disease caused by Riemerella anatipestifer (RA), also known as duck infectious serositis, new duck disease, duck septicemia, duck plague syndrome and Pasteurellosis anatipestifer. Under natural conditions, this disease occurs all year round and is one of the most serious diseases that endanger the duck farming industry. Lace ducks were immunized with Riemerella anatipestifer vaccine injections, and a toxicity test was carried out to obtain the following specific embodiments and comparative examples.

[0035] Embodiment 1:

[0036] The method for preparing the Riemerella anatipestifer vaccine injection of this embodiment comprises the following steps:

[0037] S1: preparing an aluminum gel adjuvant dispersion, comprising:

[0038] Aluminum trichloride was dissolved in deionized water to prepare an aluminum ion solution having an aluminum ion content of 0.3 mg / ml.

[0039] Sodium hydroxide with a concentration of 0.5 mol / L was gradually added to the aluminum ion solution during stirring, wherein the weight ratio of aluminum chloride to sodium hydroxide was 3:1. Sodium hydroxide solution was added dropwise as needed during the stirring process for 20 minutes to maintain the pH of the mixed solution at 7.

[0040] The mixture was allowed to stand and the supernatant was separated to obtain an aluminum gel adjuvant, and sufficient deionized water was added to wash the aluminum gel adjuvant.

[0041] The aluminum gel adjuvant is added into deionized water and stirred to obtain a colloidal aluminum gel adjuvant dispersion, wherein the aluminum ion content of the aluminum gel adjuvant dispersion is 0.3 mg / ml.

[0042] S2: preparing RA inactivated bacterial solution, including:

[0043] Preparation steps of bacterial solution: after RA freeze-dried strains are cultured and revived in CLBA blood plates, single colony bacteria are selected and inoculated into the first LB culture medium, cultured at 37°C with shaking for 20 hours, and the first generation of strains is obtained after the purity test is qualified; single colonies of the first generation of strains are selected and inoculated into the first CLBA culture medium for further culture, and the second generation of strains is obtained after the purity test is qualified; single colonies of the second generation of strains are selected and cultured in 5ml of the second LB culture medium, and after the purity test is qualified, 1% is inoculated into the third LB culture dish of 100ml, and cultured at 37°C with shaking for 20 hours, and the next step is carried out after the purity test is qualified;

[0044] Inactivation step: add formaldehyde solution to a final concentration of 0.2%, seal and treat at 37°C for 24 hours, shake once every 5 hours, take a sample and inoculate the second CLBA medium for sterility test, and proceed to the next step after passing the test;

[0045] Bacterial liquid concentration step: The bacterial liquid was centrifuged at 3000 rpm for 20 min. The obtained bacterial sludge was washed at least three times and then suspended into bacterial liquid. The concentration of the bacterial liquid was adjusted to 1.5×10 9 CFU / ml, and obtain RA inactivated bacterial solution.

[0046] S3: Houttuynia cordata sodium uses the new houttuynia cordata sodium injection produced and sold by Guangdong Yongkang Pharmaceutical Co., Ltd., wherein the concentration specification of the new houttuynia cordata sodium injection is 2 mg / ml.

[0047] S4: adding the sodium houttuyfonate and the RA inactivated bacterial solution to the aluminum gel adjuvant dispersion, wherein the volume ratio of the sodium houttuyfonate, the RA inactivated bacterial solution and the aluminum adjuvant dispersion is 1:4:8, and after mixing, separating the colloid precipitate;

[0048] S5: Using 0.75% physiological saline as an injection solvent, wherein the solute of the physiological saline is sodium chloride, the colloid precipitate is mixed with the injection solvent to obtain a Riemerella anatipestifer vaccine injection, and the Riemerella anatipestifer vaccine injection is prepared into a 0.83 ml dose.

[0049] Example 2: The difference from Example 1 is that the aluminum ion content of the aluminum gel adjuvant is 1.5 mg / ml, and the weight ratio of the houttuynia cordata sodium, RA inactivated bacteria solution and the aluminum gel adjuvant dispersion is 1:4:8.

[0050] Example 3: The difference from Example 1 is that the aluminum ion content of the aluminum gel adjuvant is 0.8 mg / ml, and the weight ratio of the houttuynia cordata sodium, RA inactivated bacteria solution and the aluminum gel adjuvant dispersion is 1:4:8.

[0051] Example 4: The difference from Example 1 is that the aluminum ion content of the aluminum gel adjuvant is 0.8 mg / ml, and the concentration of the RA inactivated bacteria solution is 1×10 9 CFU / ml, the weight ratio of the houttuynia cordata sodium, the RA inactivated bacteria solution and the aluminum gel adjuvant dispersion is 1:10:1.

[0052] Example 5: The difference from Example 1 is that the aluminum ion content of the aluminum gel adjuvant is 0.8 mg / ml, and the concentration of the RA inactivated bacteria solution is 3×10 9 CFU / ml, the weight ratio of the houttuynia cordata sodium, the RA inactivated bacteria solution and the aluminum gel adjuvant dispersion is 1:1:20.

[0053] Comparative Example 1: 0.83 ml of 0.75% saline was injected.

[0054] Comparative Example 2: No injection was given.

[0055] Comparative Example 3: Referring to the method of the paper "Zhang Siwang. Study on reducing the hemolytic side effects of houttuynia cordata sodium with submicron emulsion [D]. Southwest University; Zhang Siwang, 2010, 10-11.", the same dose of houttuynia cordata sodium as in Example 1 was prepared into a submicron emulsion, and the same dose of RA inactivated bacterial solution as in Example was directly mixed as an injection.

[0056] Comparative Example 4: Sodium houttuynia cordata with a concentration of 2 mg / ml and a bacterial solution with a concentration of 1.5×10 9 After the RA inactivated bacterial solution with a CFU / ml and the aluminum gel adjuvant dispersion with an aluminum ion concentration of 0.8 mg / ml were mixed in a volume ratio of 1:4:8, a 0.83 ml dose of injection was separated and directly injected into the recipient.

[0057] One-day-old healthy lace ducks were collected and grouped into cages. The cages were disinfected by spraying, washing, and drying. The feed troughs and waterers were cleaned every day, the feces were removed, and the floor was washed. The house was well ventilated. When the house temperature was below 10°C during the 1-6-day-old stage of the lace ducks, infrared irradiation was used to increase the temperature. The feeding method was free feeding.

[0058] 90 healthy non-immunized ducks aged 11 days were randomly divided into nine groups, each group corresponding to an embodiment or a pair of ratios, and challenged with virus inoculation in the leg muscles of lace ducks 10 days after immunization. The challenge was carried out with 4.8×10 8 CFU / 0.2mL·dose was inoculated via leg muscle route.

[0059] Any symptoms such as depression, drowsiness, weak legs, unsteady standing and walking, head shaking, difficulty breathing, crooked head and neck, and death were judged as illness, and the number of illnesses and deaths in each group of animals were counted.

[0060] Experimental Group Number of cases (only) Death (only) Example 1 5 3 Example 2 4 2 Example 3 3 1 Example 4 5 3 Example 5 4 3 Comparative Example 1 10 9 Comparative Example 2 10 10 Comparative Example 3 6 4 Comparative Example 4 7 6

[0061] From the comparison between Comparative Example 1, Comparative Example 2 and the embodiments, it can be seen that the lace ducks in Comparative Example 1 and Comparative Example 2 all showed symptoms of disease after the infection, and a large number of deaths occurred. Compared with Comparative Examples 1 and 2, the number of cases and deaths of lace ducks in the embodiments decreased. This is because after the sodium houttuynia coronatus and RA inactivated bacterial solution were mixed with the aluminum gel adjuvant, the lace ducks were able to become immune to Riemerella anatipestifer, thereby reducing the number of cases and the mortality rate.

[0062] From the comparison between each embodiment and comparative example 3, it can be seen that the mortality rate of lace ducks in each embodiment is lower than that in comparative example 3, because comparative example 3 only realizes the sustained release of houttuynia cordata sodium, and the RA inactivated bacterial solution is consumed prematurely, resulting in a decrease in the immune effect. The aluminum gel adjuvant of each embodiment can synchronously and slowly release the RA inactivated bacterial solution and houttuynia cordata sodium, fully prolonging the action time of the RA inactivated bacterial solution and houttuynia cordata sodium, and can continuously maintain the optimal concentration ratio of the RA inactivated bacterial solution and houttuynia cordata sodium in the recipient body at different time and space, continuously exerting efficient immune effects while not causing hemolysis of the recipient. Moreover, on the one hand, the aluminum gel adjuvant increases the release time of the RA inactivated bacterial solution, and on the other hand, the aluminum gel adjuvant itself has the effect of increasing the immune effect, which is conducive to continuously and better promoting the immune system of the lace duck and reducing the incidence of lace ducks.

[0063] From the comparison of Examples 1 to 5, it can be seen that the incidence and death of the lace duck in Example 3 are both low, which shows that the Riemerella anatipestifer vaccine injection of this example has a better immune effect. Compared with Example 3, the aluminum ion concentration of the aluminum gel adjuvant dispersion of Example 1 is too low, and the aluminum gel adjuvant cannot contact and adsorb the sodium houttuynia cordata and the RA inactivated bacterial solution well during the mixing stage, resulting in too little content of the sodium houttuynia cordata and the RA inactivated bacterial solution inside the aluminum gel adjuvant, thereby failing to release enough sodium houttuynia cordata and the RA inactivated bacterial solution to increase the immune effect. The aluminum ion concentration of the aluminum gel adjuvant dispersion of Example 2 is too high, resulting in the sodium houttuynia cordata and the RA inactivated bacterial solution being adsorbed too quickly during mixing, resulting in uneven distribution of the two in the aluminum gel adjuvant, and then resulting in the concentration of the sodium houttuynia cordata and the RA inactivated bacterial solution being unstable during the sustained release process, reducing the immune effect of the lace duck against Riemerella anatipestifer.

[0064] From Examples 3 to 5, it can be seen that the concentration of RA inactivated bacteria solution is 1×10 9 ~3×10 9 CFU / ml can obtain immune effect, among which the volume ratio of the aluminum gel adjuvant dispersion in Example 4 is lower than that in Example 3, and it is unable to fully adsorb the sodium houttuynia cordata and RA inactivated bacterial solution, resulting in too low content of the sodium houttuynia cordata and RA inactivated bacterial solution in the injection. The volume ratio of the aluminum gel adjuvant dispersion in Example 5 is higher than that in Example 3, resulting in the sodium houttuynia cordata and RA inactivated bacterial solution being unable to contact the aluminum gel adjuvant well during the mixing stage, resulting in insufficient adsorption, and the sodium houttuynia cordata and RA inactivated bacterial solution inside the aluminum gel adjuvant are unevenly distributed, which will also lead to the instability of the concentration of the sodium houttuynia cordata and RA inactivated bacterial solution during the sustained release process, reducing the immune effect of the lace duck against Riemerella anatipestifer.

[0065] In Comparative Example 4, although the same formula as in Example 3 was used, the concentration of 2 mg / ml of houttuynia cordata sodium and the concentration of the bacterial solution were 1.5×109 CFU / ml of RA inactivated bacterial solution and an aluminum gel adjuvant dispersion with an aluminum ion concentration of 0.8 mg / ml were mixed in a volume ratio of 1:4:8 to prepare an injection, but the lace duck still had a high morbidity and mortality rate. This was because the mixing of the three lacked the step of separating the colloid precipitate compared to Example 3. As a result, the injection was also mixed with houttuynia cordata sodium that was not fully adsorbed by the aluminum gel adjuvant. The free houttuynia cordata sodium could cause hemolysis in the lace duck, thereby leading to the morbidity and death of the lace duck.

[0066] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0067] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A method for preparing a vaccine injection, characterized in that: The steps include: Providing a colloidal aluminum gel adjuvant dispersion liquid with an aluminum ion content of 0.3 to 1.5 mg / ml, an inactivated bacterial solution and an immunopotentiator, and separating the colloidal precipitate after mixing; Mixing the colloid precipitate with an injection solvent to obtain the vaccine injection; Wherein, the immunopotentiator is selected from houttuynia cordata sodium with a concentration range of 1-3 mg / ml, and the inactivated bacterial solution is selected from a bacterial solution with a concentration of 1×10 9 ~3×10 9 CFU / ml of inactivated bacterial solution of Riemerella anatipestifer, wherein the volume ratio of the sodium houttuyfonate, the inactivated bacterial solution of Riemerella anatipestifer and the aluminum gel adjuvant dispersion is 1: (1-10): (1-20).

2. The method for preparing a vaccine injection according to claim 1, characterized in that: The preparation method of the aluminum gel adjuvant dispersion liquid in a colloidal state and having an aluminum ion content of 0.3 to 1.5 mg / ml comprises: taking an aluminum salt solution, gradually adding a water-soluble base during stirring, separating the aluminum gel adjuvant and adding deionized water to obtain an aluminum gel adjuvant dispersion liquid in a colloidal state and having an aluminum ion content of 0.3 to 1.5 mg / ml.

3. The method for preparing a vaccine injection according to claim 1, characterized in that: The injection solvent includes at least one of water, physiological saline or phosphate buffer.

4. The method for preparing a vaccine injection according to claim 1, characterized in that: The preparation steps of the sterilization solution include: Preparation steps of bacterial solution: after lyophilized strains are cultured and revived in CLBA blood plates, single colony bacteria are selected and inoculated into the first LB culture medium, cultured with shaking, and the first generation strains are obtained after the purity test is qualified; single colonies of the first generation strains are selected and inoculated into the first CLBA culture medium for further culture, and the second generation strains are obtained after the purity test is qualified; single colonies of the second generation strains are selected and cultured in the second LB culture medium, and after the purity test is qualified, 1% is inoculated into a new third LB culture dish, cultured with shaking, and the next step is performed after the purity test is qualified; Inactivation step: After adding formaldehyde solution, seal the medium and inoculate the sample into the second CLBA medium for sterility test. After passing the test, proceed to the next step; Bacterial liquid concentration step: The bacterial liquid was centrifuged, the obtained bacterial sludge was washed at least three times and then suspended into bacterial liquid, and the concentration of the bacterial liquid was adjusted to 1×10 9 ~3×10 9 CFU / ml, and obtain the inactivated bacterial solution.

5. The method for preparing a vaccine injection according to claim 4, characterized in that: The bacterial solution preparation step includes: after culturing and resuscitating the freeze-dried strain in a CLBA blood plate, selecting a single bacterial colony and inoculating it into a first LB culture medium, shaking and culturing it at 35-40° C. for 16-24 hours, and obtaining a first-generation strain after passing the purity test; selecting a single colony from the first-generation strain and inoculating it into a first CLBA culture medium for continued culturing, and obtaining a second-generation strain after passing the purity test; selecting a single colony from the second-generation strain and culturing it in a second LB culture medium, and after passing the purity test, inoculating it into a third LB culture dish at 1%, shaking and culturing it at 35-40° C. for 18-24 hours, and proceeding to the next step after passing the purity test.

6. The method for preparing a vaccine injection according to claim 4, characterized in that: The inactivation step includes: sealing treatment at a temperature of 35 to 40° C. for 16 to 32 hours, shaking once every 4 to 6 hours, sampling and inoculating into a second CLBA culture medium for sterility testing, and proceeding to the next step after passing the test.

7. The method for preparing a vaccine injection according to claim 4, characterized in that: The bacterial liquid concentration step comprises: placing the bacterial liquid in a centrifuge at 2000-4000 rpm for 10-30 min, washing the obtained bacterial sludge at least three times and then suspending it into a bacterial liquid, and adjusting the concentration of the bacterial liquid to 1×10 9 ~3×10 9 CFU / ml.

8. A vaccine injection, characterized in that: The vaccine injection is prepared by the method for preparing the vaccine injection according to any one of claims 1 to 7.